These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3975656)

  • 1. VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).
    Cavalli F
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):33-6. PubMed ID: 3975656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
    Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E
    Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [VP 16-213].
    Ogawa M
    Gan No Rinsho; 1985 May; 31(6 Suppl):774-8. PubMed ID: 3875741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
    Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST; Miller TP
    Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
    Hansen MM; Bloomfield CD; Jørgensen J; Ersbøll J; Pedersen-Bjergaard J; Blom J; Nissen NI
    Cancer Treat Rep; 1980; 64(10-11):1135-7. PubMed ID: 7459900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Wu GQ
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study.
    Dana BW; Jones SE; Coltman C; Stuckey WJ
    Cancer Treat Rep; 1986 Feb; 70(2):291-2. PubMed ID: 3753898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.